Increased CSF F2-isoprostane concentration in probable AD.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 10025788.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To quantify F2-isoprostane levels in CSF obtained from the lumbar cistern of patients with AD, ALS, and controls. Studies of human postmortem tissue and experimental models have suggested a role for oxidative damage in the pathogenesis of several neurodegenerative diseases, especially AD and ALS. F2-isoprostanes are exclusive products of free-radical-mediated peroxidation of arachidonic acid that have been widely used as quantitative biomarkers of lipid peroxidation in vivo in humans. Recently, we showed that F2-isoprostane concentrations are significantly elevated in CSF obtained postmortem from the lateral ventricles of patients with definite AD compared with controls. F2-isoprostanes were quantified by gas chromatography/negative ion chemical ionization mass spectrometry. CSF F2-isoprostanes were increased significantly in patients with probable AD, but not in ALS patients, compared with controls. Increased CSF F2-isoprostanes are not an inevitable consequence of neurodegeneration and suggest that increased brain oxidative damage may occur early in the course of AD.
Medical subject headings
- Alzheimer Disease
- Amyotrophic Lateral Sclerosis
- Dinoprost